Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotypeReport as inadecuate




Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype - Download this document for free, or read online. Document in PDF available to download.

BMC Cancer

, 10:527

First Online: 05 October 2010Received: 01 October 2009Accepted: 05 October 2010DOI: 10.1186-1471-2407-10-527

Cite this article as: Yi, S.Y., Ahn, J.S., Uhm, J.E. et al. BMC Cancer 2010 10: 527. doi:10.1186-1471-2407-10-527

Abstract

BackgroundWe analyzed the responses to first line treatment and clinical outcomes of metastatic breast cancer patients treated with palliative doxorubicin-cyclophosphamide AC according to molecular cancer subtype.

MethodsA retrospective analysis was performed for 110 metastatic breast cancer patients selected on the basis of palliative AC treatment and the availability of immunohistochemical data for estrogen receptor ER, progesterone receptor PR, and human epidermal growth factor receptor-2 HER-2-neu status.

ResultsOf the 110 patients analyzed, 71 64.5% were hormone receptor positive HR+, 14 12.7% were HER2+, and 25 22.7% were triple negative TN. There were no differences in age, stage at diagnosis, total number of cycles of palliative chemotherapy, incidence of visceral metastasis, and metastatic sites with the exception of liver among breast cancer subtypes. The overall response rates to AC were 55.9% for the HR+ subgroup, 42.9% for the HER2+ subgroup, and 56.5% for the TN subgroup. The progression-free survival PFS in patients with HER2+ and TN were significantly shorter than in the HR+ median PFS, 9.1 vs 8.1 vs 11.5 months, respectively; p = 0.0002. The overall survival OS was 25.4 months in the TN subgroup and 27.3 months in HER2+ subgroup. The median OS for these two groups was significantly shorter than for patients in the HR+ subgroup median, 38.5 months; 95% CI, 30.1-46.9 months; p < 0.0001.

ConclusionsThe response to palliative AC chemotherapy did not differ among breast cancer subtypes. Despite chemosensitivity for palliative AC, the TN subtype has a shorter overall survival than non-TN subtypes. Innovative treatment strategies should be developed to slow the course of disease.

Electronic supplementary materialThe online version of this article doi:10.1186-1471-2407-10-527 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Author: Seong Yoon Yi - Jin Seok Ahn - Ji Eun Uhm - Do Hyoung Lim - Sang Hoon Ji - Hyun Jung Jun - Kyoung Ha Kim - Myung He

Source: https://link.springer.com/







Related documents